Pyxis Oncology, Inc.
General ticker "PYXS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $147.0M (TTM average)
Pyxis Oncology, Inc. follows the US Stock Market performance with the rate: 9.5%.
Estimated limits based on current volatility of 6.1%: low 3.10$, high 3.50$
Factors to consider:
- Total employees count: 56 (+27.3%) as of 2025
- Top business risk factors: Inability to raise capital, Going concern doubt, Research failure, Regulatory and compliance, Market competition
- Current price 13.0% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.89$, 2.96$]
- 2026-12-31 to 2027-12-31 estimated range: [0.87$, 2.83$]
Financial Metrics affecting the PYXS estimates:
- Positive: with PPE of -0.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term PYXS quotes
Long-term PYXS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $16.15MM | $13.86MM |
| Operating Expenses | $82.20MM | $105.61MM | $98.28MM |
| Operating Income | $-82.20MM | $-89.46MM | $-84.42MM |
| Non-Operating Income | $8.41MM | $9.96MM | $6.18MM |
| R&D Expense | $49.59MM | $58.75MM | $73.70MM |
| Income(Loss) | $-73.79MM | $-79.50MM | $-78.23MM |
| Taxes | $0.00MM | $-2.16MM | $1.39MM |
| Net Income(Loss)* | $-73.79MM | $-77.33MM | $-79.62MM |
| Stockholders Equity | $125.70MM | $120.75MM | $53.41MM |
| Assets | $173.73MM | $157.18MM | $91.52MM |
| Operating Cash Flow | $-70.71MM | $-57.67MM | $-63.50MM |
| Capital expenditure | $6.73MM | $0.24MM | $0.01MM |
| Investing Cash Flow | $-104.85MM | $8.15MM | $58.86MM |
| Financing Cash Flow | $5.93MM | $59.33MM | $0.59MM |
| Earnings Per Share** | $-1.85 | $-1.32 | $-1.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.